Abstract
Introduction
With Pharma struggling to maintain its pipelines and portfolios with products developed in-house, companies are increasingly turning to licensing. However, the search for late-stage developmental products is becoming tougher and more expensive, and companies are now looking towards licensing earlier-stage compounds.
Scope of this report
- Overview of drivers and resistors of licensing deals, with recommendations and case study analysis of how companies can optimize the licensing process
- Examination of how to successfully navigate the licensing process, with analysis of how companies are looking to modernize their licensing strategies
- Analysis of key product deals during 2005-06, analyzing trends for in-licensing, co-development, out-licensing and marketing & promotion deals
- Assessment of drug discovery deals and technology deals, made by the top 20 pharmaceutical companies during 2005-06
Research and analysis highlights
The constant demand for late-stage product candidates has led to spiraling deal costs. Therefore companies are now looking to in-license earlier-stage compounds, demonstrated by the recent resurgence in preclinical and Phase I licensing deals made by the top 20 pharmaceutical companies.
Companies facing patent expiries of key revenue drivers between 2006-12 have in-licensed products to counteract the ensuing sales erosion. However, this tactic is not expected produce a positive growth in the short term for all companies, although it will at least offset part of their revenue deficit.
During 2005-06, Novartis was the leading dealmaker, followed by Bayer-Schering, Roche, and J&J, with the top six companies responsible for 50% of all deals made by the leading 20 companies.
Key reasons to read this report
- Understand the opportunities and threats companies face when licensing their products, and the resultant strategies some companies are employing
- Identify suitable Pharma to target when considering licensing partners for your technologies and products
- Benchmark the success of your licensing strategy in order to improve future deal making success
View Cart
